Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.
about
The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.ALK gene alterations in cancer: biological aspects and therapeutic implications.The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer.Treating ALK-positive non-small cell lung cancer.
P2860
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Current and developing therapi ...... ectives for clinical practice.
@en
type
label
Current and developing therapi ...... ectives for clinical practice.
@en
prefLabel
Current and developing therapi ...... ectives for clinical practice.
@en
P2093
P2860
P50
P1476
Current and developing therapi ...... pectives for clinical practice
@en
P2093
L Carbognin
M Brunelli
S Petraglia
P2860
P304
P356
10.1080/14656566.2016.1242578
P407
P577
2016-10-08T00:00:00Z